UBS reaffirms USD 15 target for Kura Oncology stock
Published on 10/20/2026 at 20:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and operating figures
- UBS reaffirmed its Buy rating and USD 15.00 target on October 5, 2026.
- Kura Oncology reported USD 20.87 million in second-quarter 2026 revenue.
- Kura Oncology stock costs EUR 8.85 at Lang & Schwarz on October 20, 2026 at 8:47 p.m. CEST.
- Quarterly results are scheduled for November 3, 2026.
UBS reaffirmed its Buy rating and USD 15.00 price target for Kura Oncology on October 5, 2026, according to Investing.com. The firm cited early commercial execution for Komzifti and favorable prescribing trends. Kura Oncology stock was quoted at USD 9.94 on Nasdaq on October 20, 2026 at 2:52 p.m. EDT, while the euro quote stood at EUR 8.85 at Lang & Schwarz on October 20, 2026 at 8:47 p.m. CEST.
UBS target stays above the quote
The UBS target is USD 5.06 above the Nasdaq quote, or 50.91 percent higher when measured against USD 9.94. UBS kept the Buy rating rather than changing its view, making the target a current valuation reference for the commercial-stage oncology company.
Kura Oncology's investor-relations profile describes a biotechnology business developing precision medicines for cancer and commercializing KOMZIFTI, also known as ziftomenib. The company says its pipeline includes menin inhibition and farnesyl transferase inhibition programs, according to its Kura Oncology investor page.
Stock remains below its yearly high
The Nasdaq quote of USD 9.94 was 28.49 percent below the 52-week high of USD 13.90 and 35.05 percent above the 52-week low of USD 7.36 on October 20, 2026. The market capitalization was USD 884.5 million, and trading volume reached 913,046 shares during the session.
The same Nasdaq quote carried a negative trailing price-to-earnings ratio of 2.95, so earnings-based valuation provides no positive multiple for comparison. The 52-week range instead places the stock closer to its low than its high, while UBS's USD 15.00 target sits above both the current quote and the yearly high.
Revenue rises before November results
Kura Oncology reported USD 20.87 million in second-quarter 2026 revenue, compared with USD 20.16 million expected by analysts, while its adjusted loss was USD 0.77 per share versus a USD 0.88 consensus loss, according to Investing.com. Revenue therefore exceeded the cited forecast by USD 0.71 million, or 3.52 percent.
The next reporting date is November 3, 2026, according to Yahoo Finance. That report will give investors a new operating checkpoint for Komzifti after the second-quarter launch figures.
Price and operating checkpoints
UBS's USD 15.00 target, the USD 20.87 million second-quarter revenue figure and the November 3, 2026 reporting date define the key reference points for Kura Oncology stock. The Nasdaq quote of USD 9.94 and the euro quote of EUR 8.85 provide separate market views rather than a combined currency comparison.
Kura Oncology stock was trading at EUR 8.85 at Lang & Schwarz on October 20, 2026 at 8:47 p.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of Kura Oncology stock.
Kura Oncology market facts
- Company: Kura Oncology, Inc.
- ISIN: US50127T1097
- Ticker: KURA
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 20, 2026, 8:47 p.m. CEST): EUR 8.85
- Market capitalization: USD 884.5 million (as of October 20, 2026)
- 52-week range: USD 7.36-13.90 (as of October 20, 2026)
- Sector / Industry: Healthcare / Biotechnology and Medical Research
- Next earnings date: November 3, 2026
Market context: Market report S&P 500.
